17982476

Source:http://linkedlifedata.com/resource/pubmed/id/17982476

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0016018, umls-concept:C0035647, umls-concept:C0086418, umls-concept:C0087086, umls-concept:C0332128, umls-concept:C0871161, umls-concept:C0908244, umls-concept:C1524063, umls-concept:C1533691, umls-concept:C1704675
pubmed:issue	1
pubmed:dateCreated	2008-1-7
pubmed:abstractText	Recombinant tissue-type plasminogen activator (rtPA) is the only globally approved treatment for acute ischaemic stroke. Other potential treatments might be administered with rtPA, making it important to discover whether compounds interfere with rtPA-induced lysis. We evaluated methods for examining the effect of the neuroprotectant NXY-059 on the lytic property of rtPA.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-10413033, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-11136936, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-11328677, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-11487531, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-11786485, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-12074692, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-12920263, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-12941043, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-13540201, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-1372625, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-14652110, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-15246819, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-1532403, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-16453316, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-16467546, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-16872260, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-17187399, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-17388801, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-17687131, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-17729123, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-3132929, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-4411975, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-7477192, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-8068607, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-8073394, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-8902997, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-9066003, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-9288042, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-9465840, http://linkedlifedata.com/resource/pubmed/commentcorrection/17982476-9860780
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7502536
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator, http://linkedlifedata.com/resource/pubmed/chemical/disufenton sodium
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0007-1188
pubmed:author	pubmed-author:BobinJ YJY, pubmed-author:GreenA RAR, pubmed-author:JonassonHH, pubmed-author:MattssonCC, pubmed-author:MooreN RNR, pubmed-author:MutchN JNJ
pubmed:issnType	Print
pubmed:volume	153
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	124-31
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:17982476-Benzenesulfonates, pubmed-meshheading:17982476-Dose-Response Relationship, Drug, pubmed-meshheading:17982476-Drug Interactions, pubmed-meshheading:17982476-Fibrinogen, pubmed-meshheading:17982476-Fibrinolytic Agents, pubmed-meshheading:17982476-Fluorescence, pubmed-meshheading:17982476-Humans, pubmed-meshheading:17982476-Neuroprotective Agents, pubmed-meshheading:17982476-Recombinant Proteins, pubmed-meshheading:17982476-Tissue Plasminogen Activator
pubmed:year	2008
pubmed:articleTitle	The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.
pubmed:affiliation	Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
pubmed:publicationType	Journal Article